

Chengwen Teng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2030794/publications.pdf>

Version: 2024-02-01

27
papers

514
citations

840585

11
h-index

752573

20
g-index

29
all docs

29
docs citations

29
times ranked

805
citing authors

#	ARTICLE	IF	CITATIONS
1	Virus-triggered Ubiquitination of TRAF3/6 by cIAP1/2 Is Essential for Induction of Interferon- \hat{I}^2 and Cellular Antiviral Response. <i>Journal of Biological Chemistry</i> , 2010, 285, 9470-9476.	1.6	117
2	Guanidine-Containing Methacrylamide (Co)polymers via <i>RAFT</i> : Toward a Cell-Penetrating Peptide Mimic. <i>ACS Macro Letters</i> , 2012, 1, 100-104.	2.3	78
3	<i>Clostridium difficile</i> Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. <i>International Journal of Medical Sciences</i> , 2019, 16, 630-635.	1.1	60
4	Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684515.	1.8	56
5	Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. <i>International Journal of Medical Sciences</i> , 2019, 16, 1018-1022.	1.1	31
6	Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). <i>Drug Safety</i> , 2020, 43, 17-22.	1.4	28
7	Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS). <i>Drug Safety</i> , 2020, 43, 363-369.	1.4	22
8	Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). <i>International Journal of Medical Sciences</i> , 2019, 16, 1504-1509.	1.1	20
9	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. <i>Substance Abuse: Research and Treatment</i> , 2019, 13, 117822181984420.	0.5	19
10	Mouse Embryonic Stem Cells Have Underdeveloped Antiviral Mechanisms That Can Be Exploited for the Development of mRNA-Mediated Gene Expression Strategy. <i>Stem Cells and Development</i> , 2014, 23, 594-604.	1.1	15
11	Ubiquitin-Proteasome System in Neurodegenerative Disorders. <i>Journal of Drug Metabolism & Toxicology</i> , 2015, 06, .	0.1	13
12	Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). <i>Drugs - Real World Outcomes</i> , 2022, 9, 23-29.	0.7	12
13	The in vitro activity of non-antibiotic drugs against <i>S. aureus</i> clinical strains. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 167-171.	0.9	10
14	Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G318-G327.	1.6	8
15	Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System. <i>Leukemia and Lymphoma</i> , 2021, 62, 1664-1673.	0.6	7
16	Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome. <i>Frontiers in Chemistry</i> , 2018, 6, 392.	1.8	5
17	Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study. <i>American Journal of Infection Control</i> , 2019, 47, 1053-1058.	1.1	5
18	Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. <i>Hospital Practice (1995)</i> , 2019, 47, 186-191.	0.5	3

#	ARTICLE	IF	CITATIONS
19	Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting. <i>Blood</i> , 2019, 134, 795-795.	0.6	3
20	2296. Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS). <i>Open Forum Infectious Diseases</i> , 2019, 6, S787-S787.	0.4	1
21	Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	1
22	2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S641-S641.	0.4	0
23	1881. Empiric Pseudomonal Monotherapy vs. Combination Therapy for Community-Onset Pneumonia in Older Adults. <i>Open Forum Infectious Diseases</i> , 2018, 5, S538-S539.	0.4	0
24	3542 Torsade de pointes/QT prolongation risks with antibiotics: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 57-57.	0.3	0
25	1977. Comparing Acute Kidney Injury Risk among Antibiotic Classes: A Study of the FDA Adverse Event Reporting System (FAERS). <i>Open Forum Infectious Diseases</i> , 2019, 6, S662-S662.	0.4	0
26	1596-P: Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. <i>Diabetes</i> , 2020, 69, 1596-P.	0.3	0
27	Adverse event clusters present at dose-reduction in CLL patients on ibrutinib in the U.S. Veterans Health Administration.. <i>Journal of Clinical Oncology</i> , 2020, 38, 252-252.	0.8	0